Clinical Trial Results: A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating safety, efficacy, and pharmacokinetics of paricalcitol for pediatric secondary hyperparathyroidism in stage 5 chronic kidney disease wa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperparathyroidism

Drugs mentioned

• Paricalcitol (paricalcitol)

Snippet

Sponsor: AbbVie | Conditions: Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT) | Phase 3 | Status: TERMINATED | Results posted: 2026-06-15